The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma
Bradley A. McGregor, Guru Sonpavde, Lucia Kwak, Meredith M. Regan, Xīn Gào, H. Hvidsten, Charlene Mantia, Xiao X. Wei, J.E. Berchuck, Stephanie Berg, Praful Ravi, M. Dror Michaelson, Toni K. Choueiri, Joaquim Bellmunt
Topics & Concepts
MedicineInternal medicineMetastatic Urothelial CarcinomaClinical endpointOncologyPembrolizumabAntibody-drug conjugatePhases of clinical researchUrologyGastroenterologyToxicityImmunotherapyAntibodyCancerClinical trialUrothelial carcinomaImmunologyBladder cancerMonoclonal antibodyBladder and Urothelial Cancer TreatmentsRenal cell carcinoma treatmentUrinary and Genital Oncology Studies